Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes

Authors
Yang, Hae KyungMin, Kyung WanPark, Sung WooChung, Choon HeeParks, Kyong SooChoi, Sung HeeSong, Ki-HoKim, Doo-ManLee, Moon-KyuSung, Yeon-AhBaik, Sei HyunKim, In JooCha, Bong-SooPark, Jeong HyunAhn, Yu BaeLee, In-KyuYoo, Soon JibKim, JaetaekPark, Ie ByungPark, Tae SunYoon, Kun-Ho
Issue Date
20-5월-2015
Publisher
JAPAN ENDOCRINE SOC
Keywords
DPP-4 inhibitor; Glycemic control; Type 2 diabetes
Citation
ENDOCRINE JOURNAL, v.62, no.5, pp.449 - 462
Indexed
SCIE
SCOPUS
Journal Title
ENDOCRINE JOURNAL
Volume
62
Number
5
Start Page
449
End Page
462
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/93534
DOI
10.1507/endocrj.EJ14-0544
ISSN
0918-8959
Abstract
The aim of this study was to evaluate the efficacy and safety of anagliptin in drug-nave patients with type 2 diabetes in a double-blind randomized placebo-controlled study. A total of 109 patients were randomized to 100 mg (n=37) or 200 mg (n=33) anagliptin twice daily or placebo (n=39). The primary objective was to alter HbA1c levels from baseline at a 24-week endpoint. The overall baseline mean age and body mass index were 56.20 +/- 9.77 years and 25.01 +/- 2.97 kg/m(2), respectively, and the HbA1c level was of 7.14 +/- 0.69 %. Anagliptin at 100 mg and 200 mg produced significant reductions in HbA1c (-0.50 +/- 0.45 % and -0.51 +/- 0.55%, respectively), and the placebo treatment resulted in an increase in HbA1c by 0.23 +/- 0.62 %. Both doses of anagliptin produced significant decreases in fasting plasma glucose (-0.53 +/- 1.25 mmol/L and -0.72 +/- 1.25 mmol/L, respectively) and the proinsulin/insulin ratio (-0.04 +/- 0.15 and -0.07 +/- 0.18, respectively) compared with placebo. No meaningful body weight changes from baseline were observed in three groups. Plasma dipeptidyl peptidase (DPP)-4 activity was significantly inhibited after 24 weeks of anagliptin treatment, and >75% and >90% inhibitions were observed during the meal tolerance tests with 100 mg and 200 mg anagliptin, respectively. The incidences of adverse or serious adverse events were similar among the three study groups. Twice-daily anagliptin therapy effectively inhibited DPP-4 activity and improved glycemic control and was well-tolerated in patients with type 2 diabetes.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Baik, Sei Hyun photo

Baik, Sei Hyun
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE